Biagio Ricciuti
Overview
Explore the profile of Biagio Ricciuti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
152
Citations
3822
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Barrichello A, Elkrief A, Ricciuti B, Ganta T, Marron T, Wang X, et al.
Clin Lung Cancer
. 2025 Feb;
PMID: 40021433
Background: Non-small cell lung cancer (NSCLC) patients aged ≥80 years [y] are underrepresented in clinical trials. We evaluated whether age correlates with a distinct immunophenotype or impacts outcomes to first-line...
2.
Skoulidis F, Araujo H, Do M, Qian Y, Sun X, Cobo A, et al.
Nature
. 2025 Feb;
639(8054):E19.
PMID: 40016449
No abstract available.
3.
Cortellini A, Brunetti L, Di Fazio G, Garbo E, Pinato D, Naidoo J, et al.
J Immunother Cancer
. 2025 Feb;
13(2).
PMID: 39904562
Background: Pembrolizumab monotherapy is an established front-line treatment for advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) tumor proportion score (TPS)≥50%. However, real-world data on its...
4.
Gandhi M, Elkrief A, Moore C, Ricciuti B, Alessi J, Richards A, et al.
J Thorac Oncol
. 2025 Jan;
PMID: 39864548
Introduction: Mutations in STK11, KEAP1, and SMARCA4 predispose to inferior immune checkpoint inhibitor (ICI) efficacy in NSCLC, particularly among KRAS-mutant cases. Nevertheless, the frequency, clinicopathologic features, and clinical impact of...
5.
Cappuzzo F, Ricciuti B, Delmonte A, Bonanno L, Wang X, Lye W, et al.
Clin Cancer Res
. 2025 Jan;
PMID: 39836372
Background: The role of activating alterations in the MAPK pathway in predicting immunotherapy efficacy in lung squamous cell carcinoma (LSCC) patients is largely unknown. The aims of the randomized, phase...
6.
Cooper A, Arfe A, Ricciuti B, Gagne A, Sholl L, Di Federico A, et al.
JTO Clin Res Rep
. 2025 Jan;
6(1):100759.
PMID: 39802817
Introduction: Thoracic SMARCA4-deficient undifferentiated tumors (SMARCA4-UTs) are a recently defined group of aggressive cancers in which the effectiveness of standard treatments for lung cancer is unknown. Methods: We collected clinical,...
7.
Rakaee M, Tafavvoghi M, Ricciuti B, Alessi J, Cortellini A, Citarella F, et al.
JAMA Oncol
. 2024 Dec;
11(2):109-118.
PMID: 39724105
Importance: Only a small fraction of patients with advanced non-small cell lung cancer (NSCLC) respond to immune checkpoint inhibitor (ICI) treatment. For optimal personalized NSCLC care, it is imperative to...
8.
Ricciuti B, Elkrief A, Lin J, Zhang J, Alessi J, Lamberti G, et al.
JTO Clin Res Rep
. 2024 Oct;
5(9):100675.
PMID: 39399157
Introduction: Responses to first-line programmed cell death protein 1 inhibition vary among patients with metastatic NSCLC and a programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) greater than or equal...
9.
Skoulidis F, Araujo H, Do M, Qian Y, Sun X, Cobo A, et al.
Nature
. 2024 Oct;
635(8038):462-471.
PMID: 39385035
For patients with advanced non-small-cell lung cancer (NSCLC), dual immune checkpoint blockade (ICB) with CTLA4 inhibitors and PD-1 or PD-L1 inhibitors (hereafter, PD-(L)1 inhibitors) is associated with higher rates of...
10.
Vaz V, Gandhi M, Ricciuti B, Alessi J, Elkrief A, Ladanyi M, et al.
JCO Precis Oncol
. 2024 Oct;
8:e2400394.
PMID: 39374479
Crizotinib successfully overcomes MET amplification in ROS1-rearranged NSCLC after entrectinib failure.